Patent Application for GYS1 Inhibitors

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085034A1) for N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE derivatives as inhibitors of Glycogen Synthase 1 (GYS1). The application details compounds and methods for preparing them, as well as methods for inhibiting GYS1 and treating GYS1-mediated diseases.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing novel chemical compounds identified as N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE derivatives. These compounds are claimed to be inhibitors of Glycogen Synthase 1 (GYS1). The application includes specific chemical formulas, CPC classifications, and methods for preparing these compounds, as well as methods for their use in treating GYS1-mediated diseases or conditions.

This filing does not impose immediate regulatory obligations on companies. However, it signifies potential future intellectual property rights for the inventors and could impact drug development pipelines in the pharmaceutical sector. Companies involved in GYS1 research or related therapeutic areas should monitor the progress of this patent application and similar filings for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF

Application US20260085034A1 Kind: A1 Mar 26, 2026

Inventors

David John MORGANS, JR., Kevin MELLEM, Hannah L. POWERS, Patrick Sang Tae LEE, Walter WON, Christopher Joseph SINZ

Abstract

Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. Also provided herein CN are methods of preparing compounds of formula (I). Also provided herein are methods of inhibiting GYSI and methods of treating a GYS1-mediated disease, disorder, or condition in an individual in need thereof.

CPC Classifications

C07C 233/62 A61K 31/166 A61K 31/397 A61K 31/404 A61K 31/416 A61K 31/4166 A61K 31/421 A61K 31/4439 A61K 31/445 C07C 233/63 C07C 255/46 C07D 205/04 C07D 209/34 C07D 213/40 C07D 231/12 C07D 233/74 C07D 263/58 C07D 401/10